Company: MDCXW
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001062993-25-009125
Chunk: 81

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 81
---
 Unvested at March 31, 2025
               
              257,500

              3.68

              4.69

              0.04

      As of March 31, 2025 there were $455,175 of unrecognized stock-based compensation cost related to share options outstanding, which is expected to be recognized over a weighted-average period of 2.00.
      For the three months ended March 31, 2025 and 2024, stock-based compensation expense was $112,277 and $35,953, respectively. Stock-based compensation expense has been reported in the Company's condensed consolidated statements of operations and comprehensive loss within the line items 'general and administrative' and 'research and development' expenses.

            7. Net loss per share 
            Basic and diluted net loss per share attributable to ordinary shareholders was calculated as follows:

                    Three months ended March 31,

                    2025

                    2024

                    Net loss attributable to shareholders
                    $
                    (5,102,408
                    )
                    $
                    (1,707,358
                    )

                    Weighted average number of common shares outstanding during the year
                     
                    12,240,437

                    8,076,673

                    Basic and diluted net loss per share attributable to shareholders
                    $
                    (0.42
                    )
                    $
                    (0.21
                    )

            The Company's potentially dilutive securities for the three months ended March 31, 2025 and 2024, include stock options, warrants, and notes payable. The Company excluded the potential ordinary shares outstanding at each period end from the computation of diluted net loss per share attributable to ordinary shareholders for the three months ended March 31, 2025 and 2024 because including them would have had an anti-dilutive effect.

            8. Related party transactions
             
            On October 18, 2023, the Company signed an agreement with RBx Capital, LP (“RBx”), a family office controlled by the Company’s Executive Chairman and CEO, that provides for certain managerial positions to be filled from within RBx. RBx is responsible for the payment and provision of all wages, bonuses, and benefits for these positions. Reimbursable salaries paid to RBx pursuant to this agreement are $125,000 per month. In December 2024, reimbursable salaries were changed to $100,000 per month. Reimbursable salaries